Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease A Randomized Trial

Jong, D.L.K. de; Heus, R.A.A. de; Rijpma, A.; Donders, R.; Rikkert, M.G.M.O.; Gunther, M.; Lawlor, B.A.; Osch, M.J.P. van; Claassen, J.A.H.R.

doi:doi:10.1161/HYPERTENSIONAHA.119.12892

Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8 +/- 6.2 years, mean mini-mental state examination was 20.4 +/- 3.4. Nilvadipine treatment lowered systolic blood pressure (Delta=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P<0.01), while whole-brain gray-matter CBF remained stable (Delta=5.4 [95% CI, -6.4 to 17.2] mL/100 g...Show moreCerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8 +/- 6.2 years, mean mini-mental state examination was 20.4 +/- 3.4. Nilvadipine treatment lowered systolic blood pressure (Delta=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P<0.01), while whole-brain gray-matter CBF remained stable (Delta=5.4 [95% CI, -6.4 to 17.2] mL/100 g per minute; P=0.36). CBF in the hippocampus increased (left: Delta=24.4 [95% CI, 4.3-44.5] mL/100 g per minute; P=0.02; right: Delta=20.1 [95% CI, -0.6 to 40.8] mL/100 g per minute; P=0.06). There was no significant change in CBF in the posterior cingulate cortex (Delta=5.2 [95% CI, -16.5 to 27.0] mL/100 g per minute; P=0.63) or other regions of interest. In conclusion, nilvadipine reduced blood pressure and increased CBF in the hippocampus, whereas other regions showed stable or small nonsignificant increases in CBF. These findings not only indicate preserved cerebral autoregulation in Alzheimer disease but also point toward beneficial cerebrovascular effects of antihypertensive treatment.Show less

Leiden University Scholarly Publications

View statistics

In Collections

Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease A Randomized Trial